CENESTIN Drug Patent Profile
✉ Email this page to a colleague
When do Cenestin patents expire, and when can generic versions of Cenestin launch?
Cenestin is a drug marketed by Aspen and is included in one NDA.
The generic ingredient in CENESTIN is estrogens, conjugated synthetic a. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic a profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CENESTIN?
- What are the global sales for CENESTIN?
- What is Average Wholesale Price for CENESTIN?
Summary for CENESTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,042 |
| What excipients (inactive ingredients) are in CENESTIN? | CENESTIN excipients list |
| DailyMed Link: | CENESTIN at DailyMed |
Recent Clinical Trials for CENESTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duramed Research | Phase 3 |
Paragraph IV (Patent) Challenges for CENESTIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CENESTIN | Tablets | estrogens, conjugated synthetic a | 0.3 mg, 0.45 mg and 0.9 mg | 020992 | 1 | 2009-03-19 |
| CENESTIN | Tablets | estrogens, conjugated synthetic a | 0.625 mg | 020992 | 1 | 2009-03-02 |
| CENESTIN | Tablets | estrogens, conjugated synthetic a | 1.25 mg | 020992 | 1 | 2008-11-03 |
US Patents and Regulatory Information for CENESTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-001 | Jun 21, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-003 | Mar 24, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-005 | Feb 5, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-002 | Mar 24, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-004 | Mar 13, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CENESTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-001 | Jun 21, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-003 | Mar 24, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-004 | Mar 13, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-002 | Mar 24, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | CENESTIN | estrogens, conjugated synthetic a | TABLET;ORAL | 020992-005 | Feb 5, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CENESTIN
See the table below for patents covering CENESTIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2310415 | ⤷ Sign Up | |
| Germany | 69637601 | ⤷ Sign Up | |
| Canada | 2227887 | COMPOSITIONS PHARMACEUTIQUES D'OESTROGENES CONJUGUES ET LEURS PROCEDES D'UTILISATION (PHARMACEUTICAL COMPOSITIONS OF CONJUGATED ESTROGENS AND METHODS FOR THEIR USE) | ⤷ Sign Up |
| Taiwan | 457092 | ⤷ Sign Up | |
| China | 100421652 | ⤷ Sign Up | |
| Austria | 401062 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
